James Edmondson, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1831154863
Payments from drug & device makers
Across 660 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$1K
- AstraZeneca$805
- Lilly USA, LLC$695
- Sanofi-aventis U.S. LLC$479
- Radius Health, Inc.$418
- plus $5K from 41 others
What the payments were for
- Food & beverage$10,471100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$373
How this compares
$10,476 in reported general payments places this provider in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 505 | $569,994 |
| MounjaroTirzepatide | 194 | $223,395 |
| TrulicityDulaglutide | 114 | $145,095 |
| JardianceEmpagliflozin | 109 | $118,582 |
| TymlosAbaloparatide | 22 | $79,665 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $65,090 |
| FarxigaDapagliflozin Propanediol | 72 | $59,975 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $53,564 |
| Repatha SureclickEvolocumab | 44 | $40,848 |
| RybelsusSemaglutide | 20 | $37,387 |
| Humalog Kwikpen U-100Insulin Lispro | 74 | $31,217 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $21,275 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $20,845 |
| KerendiaFinerenone | 23 | $19,933 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 40 | $18,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,290 | $607,382525 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $695 | $373,801331 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $191 | $131,856132 claims |
| Radius Health, Inc.Tymlos | $418 | $79,66522 claims |
| AstraZenecaFarxiga | $805 | $59,97572 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $479 | $20,84517 claims |
| BayerKerendia | $333 | $19,93323 claims |
| AbbVieSynthroid | $401 | $18,659155 claims |
| MerckJanuvia | $25 | $14,58512 claims |
| PfizerGenotropin | $33 | $12,83413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $255 | $2,964332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Carmella Evans-MolinaIndianapolis$6.3M
- Ernest AsamoahIndianapolis$959K
- James MaloneIndianapolis$822K
- Cary MariashIndianapolis$435K
- Marian KirkmanIndianapolis$371K
- Munro PeacockIndianapolis$197K
- Hisham AllababidiIndianapolis$195K
- James WalshIndianapolis$191K
- Michael EconsIndianapolis$182K
- Manuel Bello SeguraIndianapolis$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.